RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionIt's remarkable how those like Quentin30, who doesn't own any shares on ONCY, keep trying to post unfactual information about Bracelet-1 when we know that the PD-1 checkpoint inhibitor avelumab is unlike other CPIs given its active Fc region. ONCY's CMO Thomas Heineman has made this known in multiple presentations he has given.
" Unlike other approved anti-PD-L1 antibodies, avelumab has a native Fc region that retains FcγR binding capability."
Avelumab is cleared faster and has a shorter half-life than other anti-PD-L1 antibodies, such as atezolizumab and durvalumab, which appears to negatively impact T cell clones expansion. Consequently the addition of the PD-L1 inhibitor avelumab, unlike atezolizumab, eliminated pre-existing TIL expansion in the blood and reduced pelareorep's clinical activity, and has repeatedly proven its ineffectiveness in other clinical trials with other I/O agents besides pelareorep.
https://stockhouse.com/news/press-releases/2024/05/24/oncolytics-biotech-xae-asco-abstracts-highlight-pelareorep-s-potential-in